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Abstract
Background: Postcancer fatigue is a frequently occurring problem, impairing quality of life. Until now, little is known
about (neuro) physiological factors determining postcancer fatigue. For non-cancer patients with chronic fatigue
syndrome, certain characteristics of brain morphology and metabolism have been identified in previous studies. We
investigated whether these volumetric and metabolic traits are a reflection of fatigue in general and thus also of
importance for postcancer fatigue.
Methods: Fatigued patients were randomly assigned to either the intervention condition (cognitive behavior therapy)
or the waiting list condition. Twenty-five patients in the intervention condition and fourteen patients in the waiting list
condition were assessed twice, at baseline and six months later. Baseline measurements of 20 fatigued patients
were compared with 20 matched non-fatigued controls. All participants had completed treatment of a malignant, solid
tumor minimal one year earlier. Global brain volumes, subcortical brain volumes, metabolite tissue concentrations,
and metabolite ratios were primary outcome measures.
Results: Volumetric and metabolic parameters were not significantly different between fatigued and non-fatigued
patients. Change scores of volumetric and metabolic parameters from baseline to follow-up were not significantly
different between patients in the therapy and the waiting list group. Patients in the therapy group reported a
significant larger decrease in fatigue scores than patients in the waiting list group.
Conclusions: No relation was found between postcancer fatigue and the studied volumetric and metabolic markers.
This may suggest that, although postcancer fatigue and chronic fatigue syndrome show strong resemblances as a
clinical syndrome, the underlying physiology is different.
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Introduction
One of the well-known problems of patients undergoing
cancer treatment is fatigue [1,2]. According to longitudinal
studies, about 20 to 40% of the cancer survivors suffer from
persistent fatigue, sometimes even years after successful
completion of cancer treatment [3–7]. Postcancer fatigue is a
severe and invalidating problem, impairing quality of life [8,9].
Cognitive behavior therapy (CBT) addresses the perpetuating
factors of postcancer fatigue and has a clinically relevant effect
on reducing fatigue in severely fatigued cancer survivors [10].
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However, until now, little is known about (neuro) physiological
factors determining postcancer fatigue.
For non-cancer patients with chronic fatigue syndrome
(CFS), certain characteristics of brain morphology and
metabolism have been identified in previous studies. Using
magnetic resonance imaging (MRI) and voxel based
morphometry, in a study of 16 CFS patients and 49 healthy
controls and in another study of 28 CFS patients and 28
healthy controls, significantly reduced gray matter volumes
were observed in CFS patients compared to controls [11,12].
Interestingly, it has been shown that CBT led to a significant
increase in gray matter volume in CFS patients [13]. These
findings indicate that the cerebral atrophy associated with CFS
can be partially reversed after effective CBT [13].
In addition, altered levels of specific metabolites have been
reported in the brains of CFS patients, measured with magnetic
resonance spectroscopy (MRS). In a study of 7 CFS patients
and 10 healthy controls, a significantly reduced level of N-
acetylaspartate (NAA) was observed in the hippocampus of
CFS patients compared to controls [14]. This result has been
attributed to a reduction in neuronal and/or glial cell density or
metabolism, as NAA is a marker of neuronal and axonal
integrity [15]. The hippocampus plays a pivotal role both in
working memory and in long-term memory storage and
retrieval, which could be related to the reduced ability of CFS
patients to perform memory tasks [16].
In another MRS study of 8 CFS patients and 8 healthy
controls, the mean ratio of choline (Cho) to creatine (Cr) in the
occipital cortex was demonstrated to be significantly higher in
CFS patients compared to controls [17]. As creatine tends to
be relatively stable, this result suggests that choline is
increased in the occipital cortex of CFS patients. Increased
choline levels are associated with abnormal cell membrane
metabolism [15]. It has been hypothesized that brain
metabolites in the frontal and occipital cortex are altered in
CFS patients, because simple reaction times are longer in CFS
patients than in controls [18], and simple reaction times might
reflect the functioning of both the frontal and occipital lobes
[19].
It may be hypothesized that these metabolic and volumetric
traits found in CFS patients are a reflection of fatigue in general
and thus may also be of importance for patients suffering from
postcancer fatigue. In this study we extended the survey of
metabolites in the hippocampus with the gliosis-associated
marker myoinositol (mI) and the excitatory neurotransmitter
glutamate (Glu) and the metabolite ratios mI: NAA and Glu: mI
[20,21]. Next to global volumes of gray and white matter, as
has been studied in CFS patients, we examined subcortical
brain volumes.
The aims of this study were A) to examine if volumetric and
metabolic parameters are different between severely fatigued
and non-fatigued cancer survivors and B) to examine the effect
of CBT on these volumetric and metabolic markers in severely
fatigued cancer survivors.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Trial registration
The study is registered at ClinicalTrials.gov (NCT01096641).
Participants
The local ethics committee of the Radboud University
Nijmegen Medical Centre (RUNMC, Nijmegen, the
Netherlands) approved the study and all participants provided
written informed consent. In part A of the study, severely
fatigued and non-fatigued cancer survivors were compared
(Figure 1). In part B of the study, severely fatigued cancer
survivors were randomly assigned to either the intervention
condition or the waiting list condition (Figure 1). Fatigue
severity was measured by the fatigue severity subscale of the
Checklist Individual Strength (CIS-fatigue) [22,23]. Severe
fatigue was defined by a cut-off score of ≥35points
[7,10,24,25]. The CIS-fatigue has been used in previous
research investigating fatigue in cancer patients and was
shown to be sensitive to detect changes.
All participants had completed curative treatment of a
malignant, solid tumor or of a (non-) Hodgkin’s lymphoma a
minimum of 1 year earlier, and had no evidence of disease
recurrence at the time of the study. The minimum age of
disease onset was 18 years, patients were no older than 65
years of age when entering the study. Patients had no current
psychological or psychiatric treatment and used no anti-
depressive drugs, anti-epileptic drugs, or benzodiazepines
when participating in the study. Patients had no brain tumor in
the past and had no physical comorbidity (e.g. anemia, poor
kidney function, etc.) that could explain fatigue.
For the evaluation of severely fatigued cancer survivors,
referred for CBT to the Expert Centre for Chronic Fatigue of the
RUNMC, versus non-fatigued cancer survivors (part A of the
study), patients were included from March 2009 onwards.
Enrollment of severely fatigued cancer survivors for the
parallel-group randomized controlled trial (part B of the study)
continued in March 2010 until April 2012. Sixty-four fatigued
patients consented and were randomly assigned at a ratio of
3:1 to either the intervention condition (n=50) or the waiting list
condition (n=14). Random assignment was done by means of a
sequence of labeled cards contained in sealed, numbered
envelopes prepared by a statistical adviser. The envelopes
were opened by the psychologists in the presence of the
patient. Patients randomized to the intervention group were
immediately treated with CBT for postcancer fatigue, as
described previously [10], whereas patients randomized to the
control group waited six months for CBT and received CBT
outside the study. Both the intervention and the waiting list
group were assessed twice, at baseline and at six months
follow-up, at the RUNMC. Data are presented of patients who
completed both the baseline and follow-up measurements.
Baseline measurements of 20 of the 64 randomized severely
fatigued cancer survivors were compared with 20 age- and
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Figure 1.  Flow chart of the study.  
doi: 10.1371/journal.pone.0074638.g001
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sex-matched non-fatigued patients, recruited from the
outpatient clinics of Medical Oncology and Radiation Oncology
of the RUNMC (part A of the study). Non-fatigued patients were
assessed only once, at the RUNMC.
Measurements
MRI and MRS measurements were performed on a 3 Tesla
MR system (Tim TRIÓ, Siemens, Erlangen, Germany) using
the standard circularly polarized birdcage head coil. Fatigue
scores, global brain volumes, subcortical brain volumes,
metabolite tissue concentrations, and metabolite ratios were
the primary outcome measures.
Volumetric measurements.  High-resolution 3D T1-
weighted anatomical images of the whole brain (voxel size
1x1x1mm3) were acquired using a magnetization prepared
rapid acquisition gradient echo sequence (TR=2300 ms,
TE=3.16 ms). Raw MRI data in DICOM format were converted
to NIFTI format using the conversion as implemented in the
SPM5 package (http://www.fil.ion.ucl.ac.uk/spm/software/
spm5/).
Normalizing, bias-correcting, and segmentation of gray
matter (GM) and white matter (WM) was performed using the
voxel-based morphometry (VBM) toolbox (VBM5.1 Toolbox
version 1.19) in SPM5 using priors (default settings). This
method uses an optimized VBM protocol [26,27] as well as a
model based on Hidden Markov Random Fields (HMRF)
developed to increase signal-to-noise ratio [28]. Total GM
volume (GMV) and WM volume (WMV) were calculated by
adding the resulting tissue probabilities. Total brain volume
(TBV) was defined as the sum of WMV and GMV.
Automatic segmentation of subcortical brain structures was
performed using the FIRST module (version 1.1) of FSL
(version 4.1.4) (http://www.fmrib.ox.ac.uk/fsl) [29,30].
Volumetry was applied to segment brainstem (defined as
medulla, pons, and midbrain, bordering the ventral
diencephalon, the fourth ventricle, and the cerebellum) and
bilateral accumbens, amygdala, caudate nucleus,
hippocampus, globus pallidus, putamen, and thalamus.
Volumes of bilateral structures were added-up. Subcortical
brain volumes were expressed as a percentage of TBV.
1H Magnetic Resonance Spectroscopic Imaging.  The T1-
weighted images were used to position one 2D MR
spectroscopic image (MRSI) slice in the plane perpendicular to
the longitudinal axis of the hippocampus and a second 2D
MRSI slice in the plane including the occipital cortex. Volume
selection was done by using the semi-LASER pulse sequence
[31,32] with 12x16 phase encoding steps for MRSI in the
hippocampus and 16x20 phase encoding steps for MRSI in the
occipital cortex (nominal voxel size 10.0x10.0x10.0 mm,
TR=1500 ms, TE=30 ms for the hippocampus, TE=136 ms for
the occipital cortex, 6 acquisition-weighted averages). MRSI
data of the hippocampus were acquired with and without water
signal suppression for referencing purposes [32]. Metabolite
tissue concentrations were obtained from two voxels selected
in the hippocampus (one voxel in the right and one voxel in the
left hippocampus) and from two voxels selected in the occipital
cortex adjacent to each other, close to the parieto-occipital
sulcus. LCModel was used to obtain absolute tissue
concentrations (water referenced, corrected for T1 and T2
relaxation, but not for cerebrospinal fluid contribution) of NAA,
mI, and Glu, and the concentration ratios of mI: NAA, and Glu:
mI in the hippocampus. Signal ratios of Cho: Cr in the occipital
cortex were also obtained using LCModel. Per subject, the
metabolite tissue concentrations, metabolite concentration
ratios, and metabolite signal ratios were calculated for the two
voxels per location and subsequently averaged.
Statistics
Statistical analyses were performed using PASW for
Windows®, version 18.0.2 (Armonk, New York, USA). Results
are presented as absolute numbers, as mean ± standard
deviation (SD), as frequencies with percentages of total, or as
change scores (the percentage change from baseline to follow-
up). Normality of the data was tested using a Shapiro-Wilk test.
Chi square tests, independent samples t tests, and Mann–
Whitney U tests were performed to compare differences in
baseline characteristics between fatigued and non-fatigued
patients and between the therapy and the waiting list condition
(Table 1). To compare differences in MR results between
fatigued and sex- and age-matched non-fatigued cancer
survivors, independent samples t tests were performed (Table
2). Given the differences in brain size and morphology between
men and women [33] and the age-related changes in GM
[11,27], the normally distributed data of Table 3 are corrected
for sex and age by analyses of covariance. Differences in the
non-normally distributed parameters between the therapy and
the waiting list condition were tested by Mann–Whitney U tests
(Table 3). To evaluate the uncontrolled within group effects of
CGT and WL from baseline to follow-up, paired t tests were
performed for the normally distributed parameters and the
Wilcoxon matched-pairs tests for the non-normally distributed
parameters (Table 4). Differences were considered statistically
significant at p<0.05. The power calculation is described in the
study protocol as published previously [34]. As a result of
financial and logistic reasons, it was not possible to perform the
follow-up measurements of the patients still undergoing CBT.
Results
Patient inclusion
The flow chart of the study is presented in Figure 1. Both
severely fatigued and non-fatigued cancer survivors were
enrolled in this study between March 2009 and April 2012 and
the last follow-up measurements were performed in September
2012. Of the 66 severely fatigued patients who were referred
for CBT to the Expert Centre for Chronic Fatigue and who met
the criteria of the study, baseline data of 20 patients were
compared with data of 20 age- and sex-matched non-fatigued
patients (part A of the study). Two severely fatigued patients
refused CBT and, therefore, did not participate in the
randomized controlled trial (part B of the study). Of the 64
patients who were randomized, 50 patients were allocated to
the intervention condition and 14 patients were allocated to the
waiting list condition. After randomization, one patient had
disease recurrence, one patient was incorrectly included
according to the inclusion criteria, one patient did not want to
Postcancer Fatigue: MRI and MRS of the Brain
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start CBT, and three patients dropped out during CBT. As a
result of financial and logistic reasons, it was not possible to
perform the follow-up measurements of the 14 patients still
Table 1. Baseline characteristics of fatigued and non-
fatigued patients (part A of the study) and of fatigued
patients in the therapy and waiting list condition (part B of
the study).
 
Fatigued
(n=20)
Non-
fatigued
(n=20)
p
value
CBT
(n=25)
WL
(n=14)
p
value
Male / Female (n) 10/10 10/10 1.000
14 /
11 5 / 9 0.224
Age (years) 47.9 ±10.1
48.9 ±
9.7
0.75
1
48.8 ±
9.4
50.6 ±
10.9 0.583
Time since
cancer treatment
(months)
64.4 ±
69.7
60.1 ±
44.0
0.58
0
55.0 ±
61.7
44.4 ±
36.4 0.372
Cancer
diagnosis (n)       
Breast cancer 6 (30) 9 (45)  8 (32) 6 (43)  
Head and neck
cancer 3 (15) 2 (10)  6 (24) 2 (14)  
Testicular cancer 2 (10) 3 (15)  3 (12) 0  
(Non)Hodgkin 2 (10) 2 (10)  2 (8) 3 (21)  
Prostate cancer 2 (10) 0  2 (8) 1 (7)  
Thyroid cancer 2 (10) 0  2 (8) 0  
Other solid
cancers 3 (15) 4 (20)  2 (8) 2 (14)  
Cancer
treatment (n)       
Surgery only 2 (10) 1 (5)  3 (12) 1 (7)  
Surgery and CT 5 (25) 4 (20)  6 (24) 1 (7)  
Surgery and RT 2 (10) 2 (10)  2 (8) 2 (14)  
Surgery and RI 1 (5) 0  2 (8) 0  
Surgery and IT 0 1 (5)  0 1 (7)  
Surgery, RT and
CT 4 (20) 3 (15)  4 (16) 1 (7)  
Surgery, RT, and
HT 1 (5) 0  1 (4) 0  
Surgery, RT, and
RI 1 (5) 0  1 (4) 0  
Surgery, CT, and
HT 0 2 (10)  2 (8) 2 (14)  
Surgery, RT, CT,
and HT 2 (10) 4 (20)  2 (8) 3 (21)  
CT only 1 (5) 1 (5)  0 1 (7)  
CT and RT 1 (5) 1 (5)  1 (4) 1 (7)  
RT only 0 1 (5)  0 1 (7)  
undergoing CBT. The patients still undergoing CBT were not
included in the analyses.
Twenty-five patients completed both the baseline and follow-
up measurements in the intervention condition and 14 patients
in the waiting list condition. Due to technical failure, 3 MRI and
5 MRS measurements in the intervention condition could not
be analyzed and 2 MRS measurements in the waiting list
condition failed.
Table 1 (continued).
Data are presented as absolute numbers, as mean ± standard deviation, or as
frequencies with percentages in brackets. Independent samples t tests (age), chi
square tests (sex), and Mann Whitney-U tests (time since cancer treatment) were
performed. Abbreviations: CBT: cognitive behavior therapy; CT: chemotherapy;
HT: hormonal therapy; IT: immunotherapy; RI: radioactive iodine; RT, radiotherapy;
WL: waiting list.
doi: 10.1371/journal.pone.0074638.t001
Table 2. MR results of fatigued and non-fatigued patients.
 Fatigued (n=20)
Non-fatigued
(n=20) p value
Global brain volumes (n=20) (n=20)  
Gray matter volume (ml) 689.1 ± 76.8 661.6 ±60.4 0.449
White matter volume (ml) 530.8 ± 94.3 501.3 ± 62.4 0.703
Total brain volume (ml) 1219.9 ±153.3 1162.9 ±111.7 0.703
Subcortical brain volumes (n=20) (n=20)  
Accumbens (% of total brain volume) 0.090 ± 0.013 0.097 ± 0.018 0.150
Amygdala (% of total brain volume) 0.280 ± 0.043 0.299 ± 0.040 0.155
Caudate nucleus (% of total brain
volume) 0.606 ± 0.054 0.596 ± 0.053 0.578
Hippocampus (% of total brain
volume) 0.647 ± 0.063 0.679 ± 0.065 0.113
Globus pallidus (% of total brain
volume) 0.321 ± 0.024 0.319 ± 0.031 0.783
Putamen (% of total brain volume) 0.873 ± 0.062 0.891 ± 0.065 0.360
Thalamus (% of total brain volume) 1.318 ± 0.077 1.357 ± 0.073 0.108
Brainstem (% of total brain volume) 1.911 ± 0.130 1.957 ± 0.139 0.291
Metabolite signal ratios occipital
cortex (n=17) (n=17)  
Choline:Creatine 0.34 ± 0.07 0.37 ± 0.06 0.245
Metabolite tissue levels and
concentration ratios hippocampus (n=17) (n=17)  
N-acetylaspartate (mmol/l) 8.63 ± 0.72 8.80 ± 0.90 0.539
Myoinositol (mmol/l) 8.25 ± 1.56 7.64 ± 2.21 0.362
Glutamate (mmol/l) 7.31 ± 0.97 6.69 ± 1.32 0.128
Myoinositol:N-acetylaspartate 0.97 ± 0.23 0.87 ± 0.26 0.275
Glutamate:Myoinositol 0.92 ± 0.23 0.95 ± 0.32 0.742
Data are presented as mean ± standard deviation. Independent samples t tests
were performed. Fatigued and non-fatigued patients were matched by sex and
age.
doi: 10.1371/journal.pone.0074638.t002
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Study population
Part A) Baseline characteristics of the 20 fatigued and the 20
sex- and age-matched non-fatigued cancer survivors are
presented in Table 1. Time since cancer treatment did not
significantly differ between the patients suffering from fatigue
and the non-fatigued group. Breast cancer was the most
common cancer type. Ninety percent and 85% of the fatigued
and non-fatigued participants, respectively, underwent surgery.
Part B) Baseline characteristics of the 25 fatigued patients in
the therapy condition and the 14 patients in the waiting list
condition are presented in Table 1. Sex, age, time since cancer
treatment, and fatigue severity were similar in the intervention
and the waiting list group. Breast cancer was the most common
cancer type. Ninety-six percent and 79% of the patients in the
therapy and the waiting list condition, respectively, underwent
surgery.
At baseline, no significant differences were present in age,
sex, time since cancer treatment, and fatigue severity between
the 25 patients in the intervention condition, who completed
both the baseline and follow-up measurements, and the 25
Table 3. MR results of fatigued patients in the therapy and
waiting list condition, presented as change scores.
 CBT (n=25) WL (n=14) p value
Global brain volumes (%)
Gray matter volume
(n=22) -0.66 ±
1.39
(n=14) -0.41 ±
1.10 0.860
White matter volume -0.20 ± 0.76 -0.21 ± 0.86 0.713
Total brain volume -0.47 ± 1.04 -0.32 ± 0.66 0.987
Subcortical brain volumes (%) (n=22) (n=14)  
Accumbens -1.50 ± 8.18 0.23 ± 6.21 0.404
Amygdala 1.60 ± 6.28 2.47 ± 3.35 0.841
Caudate nucleus 0.26 ± 1.78 0.50 ± 2.00 0.688
Hippocampus -0.25 ± 2.45 -0.22 ± 2.63 0.680
Globus pallidus 0.28 ± 2.71 -0.89 ± 2.23 0.140
Putamen 0.24 ± 1.93 -0.91 ± 2.07 0.114
Thalamus 0.10 ± 1.79 0.79 ± 1.33 0.254
Brainstem 0.37 ± 3.00 -0.97 ± 2.45 0.289
Metabolite signal ratios
occipital cortex (%) (n=20) (n=12)  
Choline:Creatine -1.45 ± 40.54 3.60 ± 25.77 0.732
Metabolite tissue levels and
concentration ratios
hippocampus (%)
(n=20) (n=12)  
N-acetylaspartate 2.24 ± 10.60 0.32 ± 7.72 0.620
Myoinositol 7.32 ± 30.55 -2.97 ± 23.86 0.305
Glutamate 8.86 ± 28.61 -3.90 ± 21.02 0.233
Myoinositol:N-acetylaspartate 4.89 ± 27.22 -2.71 ± 25.58 0.413
Glutamate:Myoinositol 5.93 ± 32.60 2.02 ± 23.43 0.793
Data are presented as change scores (the percentage change from baseline to
follow-up). Analyses of covariance (subcortical brain volumes, metabolite signal
ratios occipital cortex, metabolite tissue levels and concentration ratios
hippocampus), correcting for age and sex, and Mann Whitney-U tests (global brain
volumes) were performed. Abbreviations: CBT: cognitive behavior therapy; WL:
waiting list.
doi: 10.1371/journal.pone.0074638.t003
patients in the intervention condition, for whom baseline
measurements were available only (data not shown).
Table 4. Uncontrolled within group analyses of MR results
of fatigued patients in the therapy and waiting list condition
from baseline to follow-up.
 
CBT
(n=25)
CBT
(n=25)  WL (n=14)
WL
(n=14)  
 Baseline Follow-up
p-
value Baseline
Follow-
up
p-
value
Global brain
volumes Gray matter
volume (ml)
(n=22)
686.9 ±
76.2
(n=22)
682.3.6
± 75.7
(n=22)
0.074
(n=14)
635.5 ±
65.0
(n=14)
632.6 ±
61.9
(n=14)
0.268
White matter volume
(ml)
502.8 ±
85.6
502.0 ±
87.6 0.483
496.4 ±
98.8
495.4 ±
99.2 0.542
Total brain volume
(ml)
1189.7 ±
151.9
1184.3
± 153.8 0.147
1131.9 ±
149.0
1128.0
± 145.4 0.091
Subcortical brain
volumes (n=22) (n=22) (n=22) (n=14) (n=14) (n=14)
Accumbens 0.096 ±0.014
0.095 ±
0.014 0.306
0.096 ±
0.017
0.096 ±
0.017 0.964
Amygdala 0.278 ±0.028
0.282 ±
0.029 0.275
0.300 ±
0.042
0.307 ±
0.041 0.018
Caudate nucleus 0.620 ±0.062
0.622 ±
0.065 0.466
0.627 ±
0.052
0.630 ±
0.054 0.366
Hippocampus 0.662 ±0.053
0.660 ±
0.052 0.581
0.668 ±
0.071
0.667 ±
0.076 0.828
Globus pallidus 0.319 ±0.023
0.320 ±
0.028 0.536
0.340 ±
0.025
0.337 ±
0.026 0.147
Putamen 0.877 ±0.062
0.879 ±
0.066 0.546
0.910 ±
0.038
0.902 ±
0.048 0.129
Thalamus 1.328 ±0.075
1.329 ±
0.074 0.843
1.384 ±
0.095
1.394 ±
0.095 0.049
Brainstem 1.898 ±0.171
1.921 ±
0.182 0.071
2.033 ±
0.178
2.016 ±
0.134 0.360
Metabolite signal
ratios occipital
cortex
(n=20) (n=20) (n=20) (n=12) (n=12) (n=12)
Choline:Creatine 0.37 ±0.10
0.34 ±
0.09 0.336
0.35 ±
0.10
0.35 ±
0.07 0.860
Metabolite tissue
levels and
concentration ratios
hippocampus
(n=20) (n=20) (n=20) (n=12) (n=12) (n=12)
N-acetylaspartate 8.80 ±0.93
8.95 ±
0.91 0.476
8.92 ±
0.63
8.92 ±
0.65 0.981
Myoinositol 7.93 ±1.74
8.22 ±
1.74 0.537
8.35 ±
1.32
7.96 ±
1.76 0.498
Glutamate 7.08 ±1.24
7.44 ±
1.11 0.360
7.43 ±
0.73
7.05 ±
1.28 0.422
Myoinositol:N-
acetylaspartate
0.92 ±
0.25
0.92 ±
0.20 0.893
0.94 ±
0.14
0.89 ±
0.19 0.503
Glutamate:Myoinositol 0.93 ±0.24
0.95 ±
0.28 0.733
0.91 ±
0.16
0.92 ±
0.22 0.895
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Part A. Fatigued versus non-fatigued patients
Subcortical brain volumes (accumbens, amygdala, caudate
nucleus, hippocampus, globus pallidus, putamen, thalamus,
and brainstem, Figure 2A–C) and global brain volumes (GMW,
WMV, and TBV, Figure 2D–F) were not significantly different
between fatigued and non-fatigued patients (Table 2). In the
hippocampus, metabolite tissue concentrations (NAA, mI, and
Glu) and metabolite concentration ratios (mI: NAA and Glu: mI)
did not significantly differ between fatigued and non-fatigued
patients (Table 2 and Figure 3). Finally, metabolite signal ratios
in the occipital cortex (Cho: Cr) were not significantly different
between fatigued and non-fatigued patients (Table 2 and
Figure 3).
Part B. Cognitive behavior therapy versus waiting list
After 6 months follow-up, patients who underwent CBT, with
a mean of 11.8±5.1 individual sessions, reported a significantly
larger change in fatigue scores than patients who waited 6
Table 4 (continued).
Data are presented as mean ± standard deviation. P-values of uncontrolled within
group analyses from baseline to follow-up are presented for the therapy and
waiting list condition. Paired t tests (subcortical brain volumes, metabolite signal
ratios occipital cortex, metabolite tissue levels and concentration ratios
hippocampus) and Wilcoxon matched-pairs tests (global brain volumes) were
performed. Abbreviations: CBT: cognitive behavior therapy; WL: waiting list.
doi: 10.1371/journal.pone.0074638.t004
Figure 2.  Examples of subcortical and global brain
segmentation.  An example of subcortical brain segmentation
of the thalamus in red in coronal (A), sagittal (B), and
transversal plane (C), and an example of voxel-based
segmentation of an anatomical image (D) in a gray matter
image (E) and a white matter image (F).
doi: 10.1371/journal.pone.0074638.g002
months for CBT (p<0.001, respectively -45.5±22.7% and
-16.4±25.0%).
Change scores (percentage change from baseline to follow-
up) of global brain volumes (GMW, WMV, and TBV) and
subcortical brain volumes (accumbens, amygdala, caudate
nucleus, hippocampus, globus pallidus, putamen, thalamus,
and brainstem) were not significantly different between patients
in the therapy group and patients in the waiting list group
(Table 3). In the hippocampus, metabolite tissue
concentrations (NAA, mI, and Glu) and metabolite
concentration ratios (mI: NAA and Glu: mI) were not
significantly different between patients in the therapy group and
patients in the waiting list group (Table 3). Also, metabolite
signal ratios in the occipital cortex (Cho: Cr) did not significantly
differ between patients in the therapy and patients in the
waiting list group (Table 3).
Uncontrolled within group analyses showed no significant
effect of CBT from baseline to follow-up on global brain
volumes, subcortical brain volumes, metabolite tissue
concentrations, metabolite concentration ratios, and metabolite
signal ratios (Table 4). The WL condition showed also no effect
from baseline to follow-up on these volumetric and metabolic
parameters, except for a significant increase in the volume of
the amygdala and the thalamus (Table 4).
Discussion
To the best of our knowledge, this is the first study to report
on volumetric and metabolic parameters in the brain of
severely fatigued and non-fatigued disease-free cancer
Figure 3.  Examples of spectra, background images, and
1H Magnetic Resonance Spectroscopic Imaging grid.  An
example of a Hanning filtered spectrum in the occipital cortex
(A) and in the hippocampus (B) and the accompanying
background image plus 1H Magnetic Resonance Spectroscopic
Imaging grid (respectively C and D).
doi: 10.1371/journal.pone.0074638.g003
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survivors. In contrast to findings in CFS, no volumetric and
metabolic differences between fatigued and non-fatigued
cancer survivors were observed. In addition, this is the first
randomized controlled trial examining the effect of CBT on
volumetric and metabolic markers in severely fatigued disease-
free cancer survivors. CBT for fatigue in cancer survivors is an
effective therapy, as has been shown before [10]. In our study
CBT also resulted in a significantly larger decrease in fatigue
severity compared to a period of waiting for therapy. However,
we did not observe significant effects of CBT on volumetric or
metabolic markers in the brain.
In the study of de Lange et al. [13], gray matter volume was
significantly smaller in CFS patients (669.4 ± 14.4 ml)
compared to healthy controls (708.2 ± 12.0 ml) and CFS
patients showed a significant increase in gray matter volume
from pre-CBT to post-CBT (674.1 ± 15.1 ml). Although not
significantly different between fatigued and non-fatigued cancer
survivors, the gray matter volumes were comparable to the
CFS study. In fatigued patients, gray matter volume did not
significantly change from pre- to post-CBT or from pre- to post-
waiting list. In both studies, anatomical images were acquired
using a magnetization prepared rapid acquisition gradient echo
sequence and images were analyzed using VBM. The duration
of fatigue complaints was comparable in the CFS study (CFS
duration in years in CFS patients 5.8 ± 0.79) and the present
study (time since cancer treatment in years in fatigued cancer
survivors 5.4 ± 5.8). The CFS study was performed at 1.5
Tesla, whereas the present study was performed on a 3.0
Tesla scanner with a better signal-to-noise ratio. Although we
did not find significant differences in global brain volumes in the
present study, the VBM method is able to demonstrate
significant differences between groups, as has been shown
before [11–13].
We extended the survey of global brain volumes and
examined subcortical brain volumes, but found no associations
with postcancer fatigue. This analysis method has shown the
potential to detect small differences in subcortical brain
volumes, however, in larger groups of subjects [29,35].
The absolute and relative tissue levels of the metabolites
determined in this study for non-fatigued patients are
comparable with values commonly found for the hippocampus
and occipital cortex in normal persons [32,36–38]. However,
the decreased levels of NAA in the hippocampus, as found in
CFS patients [14], were not observed in our patients with
postcancer fatigue. This CFS study concerned far less patients
than in our study. It was performed on a 1.5 Tesla MR system
and the spectra were acquired using a STEAM sequence,
whereas the present study was performed on a 3.0 Tesla MR
system and used a semi-LASER sequence, which results in a
much better signal-to-noise ratio. Moreover, the T2 relaxation
times of the individual metabolites measured at three different
echo times in the CFS study are susceptible to small noise
contributions, a rather high absolute NAA concentration was
reported for healthy controls, and the levels of all main
metabolites seemed to decrease for CFS patients compared to
healthy controls.
We also could not observe a difference in the Cho: Cr ratio
for postcancer fatigues patients as seen in the occipital cortex
in another study of CFS patients [17]. This CSF study also
concerned a much smaller patient group and was performed at
1.5 Tesla, but further described settings were comparable to
the current investigation. An increased ratio of Cho: Cr was
also observed in the basal ganglia of another small group of
CFS patients [39].
Furthermore, no significant differences could be found
between fatigued and non-fatigued cancer survivors for any
other investigated metabolite level, such as the Glu tissue
concentrations in the hippocampus.
Altogether, the results of our study could not confirm the
hypothesis that metabolic and volumetric traits observed in
CFS patients are a reflection of fatigue in general and are,
therefore, also of importance for patients suffering from
postcancer fatigue. This suggests either that, although
postcancer fatigue and CFS show strong resemblances as a
clinical syndrome, the underlying physiology is different, or that
technical differences between the present study in postcancer
fatigue and the previous studies in CFS patients explain the
differences in study outcomes between both fatigue
syndromes. The more likely reason for the observed
differences between postcancer fatigue and CFS in metabolite
concentrations and ratios may lie in the technical arena, in
particular because of the much smaller group sizes and more
unfavorable measurement conditions (e.g. lower magnetic
fields) in the CFS studies. A direct comparison of the data of
the present postcancer fatigue study with the data acquired in a
CFS study with the same technical parameters and the same
sample size is necessary to address this discrepancy.
Postcancer fatigue appears to be unrelated to abnormalities
in brain structure or brain metabolite concentrations, but our
results do not imply that alterations in the pathophysiology of
the brain can be excluded as underlying mechanism of
postcancer fatigue. In particular, alterations in the dynamics of
brain physiology, which are not reflected in the static levels of
the brain metabolites or in the brain volumes as investigated in
this study may be involved. To address if these aspects of
brain physiology contribute to the experience of fatigue, it is
needed to perform more functional studies such as, for
example, resting state functional MRI [40].
Limitations of the study
We could have investigated more areas in the brain for
metabolic differences and the number of patients might still
have been relatively small, although the group size was much
larger than in comparable studies. Also, the power of the study
was sufficiently high to demonstrate a significantly larger
decrease in CIS-fatigue score in patients in the therapy group
compared to patients in the waiting list group.
In conclusion, no relation was observed between postcancer
fatigue and a set of volumetric and metabolic markers in the
brain in the present study. Therefore, based on the VBM
method to calculate global brain volumes, the FIRST module of
FSL to calculate subcortical brain volumes, and 1H MRSI to
calculate metabolite concentrations and ratios in the
hippocampus and the occipital cortex, postcancer fatigue does
not appear to be associated with abnormalities in brain
structures or brain metabolism. Additional investigations,
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including functional brain studies, may be needed to identify
neurophysiological factors which may explain postcancer
fatigue.
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